secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2023-11-29T23:59:59+00:00
Accession:  0001728117-23-000157
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

John Quisel appointed to Gossamer Bio Board; brings PAH expertise from Acceleron/Merck
--------------------------------------------------------------------------------

- Appointed Class III director, term expiring at 2024 annual meeting; joins Audit Committee.
- Received option to purchase 230,000 shares vesting monthly over three years, plus $40,000 board retainer and $7,500 audit retainer annually.
- Currently President & CEO of Disc Medicine; previously at Acceleron Pharma leading re-acquisition of sotatercept rights for PAH from Bristol-Myers Squibb.
- Led initiative that culminated in Merck's $11B acquisition of Acceleron in 2021, highlighting deep PAH corporate development experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811723000157/0001728117-23-000157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811723000157/goss-20231128.htm
  HTML page:      https://secwatch.observer/filing/0001728117-23-000157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer